CHMP Recommends Brodalumab (Kyntheum) for Plaque Psoriasis

The EMA's CHMP has recommended granting marketing authorization for brodalumab (Kyntheum, LEO Pharma, A/S) for the treatment of adults with moderate to severe plaque psoriasis.
International Approvals

http://ift.tt/2qzMasE